EBITDA jumped 40% to Rs 281.6 crore in Q3 FY26, registering the growth of 40% compared with Rs 271.8 crore in Q3 FY25.EBITDA margin improved to 34.6% in Q3 FY26 as against 30.5% in Q3 FY25.

Sachin K. Gupta, founder & Global CEO, IKS Health,said, “"Our strong Q3 performance, characterized by 24% revenue growth, validatesthat our Care Enablement Platform is the critical solution for a US healthcare market facing a perfect storm of cost, quality, and access pressures. As physician marginsface renewed compression from stagnant reimbursement rates, we are seeing this act as a powerful catalyst for increased outsourcing and platform adoption.

We continue to deepen our value proposition by advancing our AI capabilities—specifically moving our Patient Engagement suite toward multi-agent orchestration—to drive cognitive reasoning and independent action. Our recent wins with partners like StrideCare and VitalMD demonstrate that provider enterprises are increasingly choosing our integrated platform to ensure their financial sustainability and clinical efficiency.”

Nithya Balasubramanian, Group CFO, IKS Health said, “Our Q3 FY2026 performance underscores our consistent ability to drive profitable growth and deliver significant value to our clients. We achieved a 24% year-on-year revenue increase and a 41% growth in Profit After Tax (PAT), fueled by continuous expansion across existing and new client relationships. Margin expansion is a direct result of our successful operating leverage, technology deployment and focused cost management. ”

Inventurus Knowledge Solutions (IKS Health) is a leading technology enabled healthcare solutions provider, primarily serving the US healthcare market. It offers a comprehensive care enablement platform that supports healthcare enterprises across outpatient and inpatient care settings.